glp 1 agonists and pancreatitis Reconciling GLP-1s The pancreatic and extrapancreatic effect

13 In this review, we summarise the evidence related to the effects of GLP-1 RAs on these outcomes ( Figure 1 ), which may shed light on the potential of these agents to be used in the clinical care of HF patients and investigated in large clinical trials to evaluate clinical outcomes

Cash-Pay Patients If paying out-of-pocket regardless of brand: Zepbound: $1,069/month Compounded tirzepatide: $349/month Save $720/month ($8,640/year) with compounded option Availability Considerations: Shortage Status: Both Mounjaro and Zepbound have experienced shortages: High demand exceeding manufacturing capacity No guarantee either is available at your pharmacy May need to call multiple pharmacies Wait times of weeks to months during shortages Supply is improving as of late 2025, but intermittent shortages still occur

Sourced from licensed U.S

Drug-Metabolizing Enzyme- and Transporter- Mediated DDIs of GLP-1 RAs and a Dual GLP-1/GIP RA To date, no clinically relevant drug-metabolizing enzyme- or transporter-mediated DDIs involving GLP-1 RAs or a dual GLP-1/GIP RA have been reported (Table 3)